"This clinical trial leverages CCR's established track record studying novel treatments for PTSD and other difficult to treat mental health conditions."ĬCR is experienced in hosting pediatric and adult phase I-IV clinical trials and investigator-led studies across a wide range of mental health conditions. Reid Robison, Chief Medical Officer of Novamind and Principal Investigator at CCR. "We look forward to investigating BNC210 as a potential treatment for PTSD, a condition that is in need of new treatment options," said Dr. Food and Drug Administration (FDA), a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. In 2019, BNC210 received a Fast Track Designation from the U.S. PTSD is associated with a wide range of problems, including difficulties at work, social dysfunction and physical health problems. Lifetime and past-year prevalence rates of PTSD among American adults are 8.3 percent and 4.7 percent, respectively 1. ![]() The Bionomics study is titled "A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder ("PTSD")". (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its wholly owned subsidiary, Cedar Clinical Research ("CCR") has been selected as a research site for a clinical trial sponsored by Bionomics Limited ("Bionomics"). TORONTO, ON / ACCESSWIRE / J/ Novamind Inc. Cedar Clinical Research to Host Phase IIb Trial for a Novel PTSD Treatment
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |